Literature DB >> 8673704

DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes.

A Shibuya1, D Campbell, C Hannum, H Yssel, K Franz-Bacon, T McClanahan, T Kitamura, J Nicholl, G R Sutherland, L L Lanier, J H Phillips.   

Abstract

Intercellular adhesion molecules play an important role in the generation of T lymphocyte-mediated immune responses. Here, we describe a novel accessory molecule, DNAX accessory molecule-1 (DNAM-1), that is constitutively expressed on the majority of peripheral blood T lymphocytes. DNAM-1 is a 65 kDa transmembrane glycoprotein consisting of 318 aa including two immunoglobulin-like domains. Anti-DNAM-1 monoclonal antibody (MAb) inhibits T and NK cell-mediated cytotoxicity against a variety of tumor cell targets and blocks cytokine production by alloantigen-specific T cells. In addition, DNAM-1 is a tyrosine-phosphorylated signal-transducing molecule that participates in primary adhesion during cytotoxic T lymphocyte (CTL)-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673704     DOI: 10.1016/s1074-7613(00)70060-4

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  204 in total

1.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1.

Authors:  Jiuyu Gong; Rongrong Liu; Ran Zhuang; Yun Zhang; Liang Fang; Zhuwei Xu; Liang Jin; Tao Wang; Chaojun Song; Kun Yang; Yuying Wei; Angang Yang; Boquan Jin; Lihua Chen
Journal:  Cancer Sci       Date:  2012-02-13       Impact factor: 6.716

3.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

4.  Hypomethylation within gene promoter regions and type 1 diabetes in discordant monozygotic twins.

Authors:  Emon Elboudwarej; Michael Cole; Farren B S Briggs; Alexandra Fouts; Pamela R Fain; Hong Quach; Diana Quach; Elizabeth Sinclair; Lindsey A Criswell; Julie A Lane; Andrea K Steck; Lisa F Barcellos; Janelle A Noble
Journal:  J Autoimmun       Date:  2016-01-09       Impact factor: 7.094

5.  CD226 rs763361 (Gly307Ser) polymorphism is associated with susceptibility to rheumatoid arthritis in Zahedan, southeast Iran.

Authors:  Mohammad Hashemi; Zahra Zakeri; Ebrahim Eskandari-Nasab; Mahdi Atabaki; Seyed Mohammad Ebrahim Pourhosseini; Mehdi Jahantigh; Gholamreza Bahari; Mohsen Taheri
Journal:  Iran Biomed J       Date:  2013

6.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion.

Authors:  Yenan T Bryceson; Michael E March; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

7.  CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:  Amelia Roman Aguilera; Viviana P Lutzky; Deepak Mittal; Xian-Yang Li; Kimberley Stannard; Kazuyoshi Takeda; Günter Bernhardt; Michele W L Teng; William C Dougall; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

8.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

Review 9.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 10.  Next generation treatment of acute graft-versus-host disease.

Authors:  J Magenau; P Reddy
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.